The global hypereosinophilic syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hypereosinophilic syndrome (HES) is a group of blood disorders. It occurs due to the high numbers of eosinophils or white blood cells. Over time, the excess eosinophils enter various tissues which eventually damages the organs. The major factor driving the market growth include the increasing prevalence of hypereosinophilic syndrome across the globe. Moreover, the market is also growing owing to the promising pipeline drugs. Additionally, high diagnostic rates coupled with improvement in healthcare facilities are propelling the market growth. However, the market growth is hampered due to the limited revenue opportunities coupled with high treatment costs.
To Request a Sample of our Report on Hypereosinophilic Syndrome Drug Market: https://www.omrglobal.com/request-sample/hypereosinophilic-syndrome-drug-market
Some major players operating in the market include Bristol-Myers Squibb Co., GlaxoSmithKline Plc, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2020, GlaxoSmithKline plc (GSK) announced the approval of Nucala (mepolizumab) from the US Food and Drug Administration (FDA). It is used for the treatment of Hypereosinophilic Syndrome (HES) for more than six months without an identifiable non-haematologic secondary cause in adult and paediatric patients aged 12 years and older.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Bristol-Myers Squibb Co., GlaxoSmithKline Plc, and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Hypereosinophilic Syndrome Drug Market is Available @ https://www.omrglobal.com/industry-reports/hypereosinophilic-syndrome-drug-market
Global Hypereosinophilic Syndrome Drug Market Report by Segment
By Type
- Benralizumab
- Dasatinib
- Dexpramipexole Dihydrochloride
- Mepolizumab
- Others
By Application
- Hospital
- Clinic
- Others
Global Hypereosinophilic Syndrome Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
